Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker BEFREE A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma. 31241175

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker BEFREE We studied the association of immunohistochemical expression of hypoxia inducible factor-1 alpha (HIF-1α), telomerase reverse transcriptase (TERT), isocitrate dehydrogenase 1 (IDH1) and tumor protein p53 with overall survival (OS) in glioblastoma patients uniformly treated by standard of care, with adequate follow-up. 31258744

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 AlteredExpression BEFREE To evaluate the frequency of MGMT methylation status in a single institute series of 134 GBMs and correlate it with clinical (age, sex, location, survival) and other molecular parameters [such as p53 expression, alpha thalassemia/mental retardation syndrome X-linked (ATRX) expression, isocitrate dehydrogenase (IDH) 1R132H mutation, and epidermal growth factor receptor (EGFR) gene amplification]. 30038102

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker BEFREE We found that HR indeed regulates p53 target genes, including those implicated in cell cycle progression and apoptosis in the GBM-derived U87 cell line, and restoring HR expression triggered G2/M arrest and apoptosis. 30191601

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker BEFREE Our recent study indicated that TSN has anti-cancer effect in glioblastoma through induction of estrogen receptor β (ERβ) and p53. 29629572

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker BEFREE Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma. 30940658

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker BEFREE Alkylaminophenol Induces G1/S Phase Cell Cycle Arrest in Glioblastoma Cells Through p53 and Cyclin-Dependent Kinase Signaling Pathway. 31001122

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker BEFREE To determine whether there is a threshold for the TMZ-induced DNA damage response and exploring the factors regulating the switch between p53 dependent survival and death, the glioblastoma lines LN-229 (deficient in MGMT) and LN-229MGMT (stably transfected with MGMT) were exposed to different doses of TMZ. p53 protein expression and phosphorylation levels of p-p53ser15 and p-p53ser46 were determined by Western blotting. 30925722

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker BEFREE Impairment of IMPDH2 activity triggers nucleolar stress and growth arrest of glioblastoma cells even in the absence of functional p53. 31371825

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 AlteredExpression BEFREE Role of asparagine endopeptidase in mediating wild-type p53 inactivation of glioblastoma. 31400201

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker BEFREE Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide. 31081046

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 GeneticVariation BEFREE We investigated the role of MTBP in the biology of TP53-wildtype (TP53wt) GBMs. 31534534

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker BEFREE More than 1700 proteins were quantified, and bioinformatics predicted activations of MYC, NFE2L2, FN1, and TGFβ1 and inhibition of TP53 in GBM-EV stimulated astrocytes that were then confirmed by qPCR. 30353492

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker BEFREE In this study, biotinylated PAMAM G3 dendrimers substituted with the recognized anticancer agents cyclooxygenase-2 (COX-2) inhibitor celecoxib and peroxisome proliferator-activated receptor γ (PPARγ) agonist Fmoc-L-Leucine (G3-BCL) were tested in vitro on human cell lines with different p53 status: glioblastoma (U-118 MG), normal fibroblasts (BJ) and immortalized keratinocytes (HaCaT). 31652556

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker BEFREE Effects of RG7388 and radiotherapy were analyzed in p53 wild-type glioblastoma cell lines and glioma-initiating cells. 30274984

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker BEFREE Quantitative morphological tumor characteristics on post-contrast T1-weighted MRI can to a certain degree provide insights regarding Ki67 and p53 status in patients with glioblastoma. 31020343

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 AlteredExpression BEFREE The Kaplan-Meier survival plot illustrated poor survival in glioblastoma patients with over-expressed LINC-ROR ( P=0.010) and down-regulated p53 ( P=0.002). 30852975

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker BEFREE This antagonism results in increased p53 activity and can also re-activates the p53 pathway and resensitize the glioblastoma cells to apoptosis. 30656973

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker BEFREE An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFRα Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. 30594071

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker BEFREE We suppose that performing a standard molecular analysis (IDH, EGFR, p53 and Ki67) is not sufficient to predict the behavior of a GBM in regards to overall survival (OS), nor to provide a deeper understanding of the meaning of the different genetic alterations in the DNA of cancer cells. 31801254

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 GeneticVariation BEFREE BRCA1 identified as a modulator of temozolomide resistance in P53 wild-type GBM using a high-throughput shRNA-based synthetic lethality screening. 31815044

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker BEFREE We used CRN2 knock-out mice for analyses as well as for crossbreeding with a Tp53/Pten knock-out glioblastoma mouse model. 31677819

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker BEFREE Correlation analysis of expressions of PTEN and p53 with the value obtained by magnetic resonance spectroscopy and apparent diffusion coefficient in the tumor and the tumor-adjacent area in magnetic resonance imaging for glioblastoma. 29745082

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 GeneticVariation BEFREE Mean Ki-67 labeling index was 29% (range, 1.5%-80%). p53 mutation was present in 20/36 GBs (55%), whereas OLIG2 expression was positive in 29/36 GBs (80.5%). 31003026

2019

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.400 Biomarker BEFREE Specifically, targeting cellular pathways frequently altered in glioblastoma, such as the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), the p53 and the retinoblastoma (RB) pathways, or epidermal growth factor receptor (EGFR) gene amplification or mutation, have failed to improve outcome, likely because of redundant compensatory mechanisms, insufficient target coverage related in part to the blood brain barrier, or poor tolerability and safety. 31541850

2019